Efficacy of Intravenous Glyco-P® in Patients Undergoing Procedure That Require Anesthesia Service
|ClinicalTrials.gov Identifier: NCT02102542|
Recruitment Status : Completed
First Posted : April 3, 2014
Last Update Posted : April 3, 2014
|Condition or disease|
|Hypersalivation Prevention of Drooling Bradycardia Reversal of Muscle Relaxants|
Show Detailed Description
|Study Type :||Observational|
|Estimated Enrollment :||65 participants|
|Official Title:||Efficacy of Intravenous Glyco-P® in Patients Undergoing Procedure That Require Anesthesia Service|
|Study Start Date :||July 2012|
|Actual Primary Completion Date :||March 2013|
|Actual Study Completion Date :||April 2013|
A group of patients enrolled to prove efficacy of Glyco-P for reduction of secretions.
A group of patients enrolled to prove efficacy of Glyco-P for modest increase of heart rate.
For reversal of neuromuscular blocking agents
Group of patients enrolled to prove efficacy of Glyco-P when used in combination with neostigmine to reserve neuromuscular blocking agents.
- Efficacy of Glyco-P as an antisialagogue [ Time Frame: 3 months ]Examine efficacy of Glyco-P for reduction of secretion and also for prevention of secretion. The secretions score ranges from 0-5 was evaluated by a person who was blinded to treatment before and after treatment.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02102542
|Anesthesiology Department Siriraj Hospital|
|Bangkoknoi, Bangkok, Thailand, 10700|